Diversify Wealth Management LLC Boosts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Diversify Wealth Management LLC raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 160.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,773 shares of the pharmaceutical company’s stock after purchasing an additional 6,027 shares during the quarter. Diversify Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $4,002,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of VRTX. Mutual Advisors LLC raised its position in Vertex Pharmaceuticals by 0.6% during the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company’s stock worth $1,751,000 after buying an additional 21 shares during the last quarter. Daymark Wealth Partners LLC increased its stake in shares of Vertex Pharmaceuticals by 2.8% during the third quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company’s stock worth $374,000 after acquiring an additional 22 shares during the period. Grove Bank & Trust raised its holdings in Vertex Pharmaceuticals by 5.7% during the third quarter. Grove Bank & Trust now owns 410 shares of the pharmaceutical company’s stock worth $191,000 after purchasing an additional 22 shares in the last quarter. Outlook Wealth Advisors LLC lifted its position in Vertex Pharmaceuticals by 2.8% in the third quarter. Outlook Wealth Advisors LLC now owns 892 shares of the pharmaceutical company’s stock valued at $415,000 after purchasing an additional 24 shares during the period. Finally, Dunhill Financial LLC boosted its holdings in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

VRTX has been the subject of several recent analyst reports. Barclays reduced their price target on Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating for the company in a report on Friday, December 20th. UBS Group boosted their target price on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Stifel Nicolaus increased their price target on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a report on Monday, December 16th. Wells Fargo & Company decreased their price objective on shares of Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Finally, Oppenheimer cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $490.38.

Vertex Pharmaceuticals Stock Up 1.2 %

NASDAQ VRTX opened at $422.00 on Monday. The business’s 50-day moving average price is $440.94 and its 200 day moving average price is $466.09. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. During the same period in the prior year, the firm posted $3.67 EPS. The company’s revenue was up 11.6% on a year-over-year basis. Research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.